Back | Next |
home / stock / nbrv / nbrv message board
Subject | By | Source | When |
---|---|---|---|
$NBRV .25'S here | TheFinalCD | investorshub | 09/15/2022 2:29:54 PM |
Im in. Let run it | Pennystock_snipers | investorshub | 09/15/2022 2:29:20 PM |
NBRV .28 pretty quiet over here | TheFinalCD | investorshub | 09/15/2022 1:27:27 PM |
R/S tomorrow. | subslover | investorshub | 09/15/2022 12:28:07 PM |
---- Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory | John-Knee | investorshub | 10/04/2021 9:15:18 PM |
Is this gonna be delisted?... | rynlrt | investorshub | 07/15/2021 6:12:46 PM |
$1.39 for me | falkus951 | investorshub | 06/03/2021 4:38:45 PM |
No fair. almost nailing bottom for yourself. | swampboots | investorshub | 05/27/2021 7:56:48 PM |
Took a lotto $1.38 | DD-214 | investorshub | 05/27/2021 3:00:53 PM |
$NBRV 1.41 near yearly lows, and wins hand | swampboots | investorshub | 05/27/2021 2:40:35 PM |
* * $NBRV Video Chart 05-26-2021 * * | ClayTrader | investorshub | 05/26/2021 9:02:21 PM |
lot of ill will towards this company from | saigai | investorshub | 05/26/2021 5:20:58 PM |
good luck...i usually dont buy the gap but | saigai | investorshub | 05/26/2021 1:47:46 PM |
Looks good got in $$$ | INFINITI | investorshub | 05/26/2021 1:42:58 PM |
lived in china for 10 years..every time someone | saigai | investorshub | 05/26/2021 12:25:07 PM |
Nabriva Therapeutics Phase 3 Trial of Antibiotic Medication | John-Knee | investorshub | 05/26/2021 11:15:21 AM |
BRIEF-Sinovant Sciences And Nabriva Therapeutics Announce Positive Topline | John-Knee | investorshub | 05/25/2021 10:58:39 PM |
Study Demonstrates Macrolide-Resistance in S. pneumoniae in the | John-Knee | investorshub | 02/23/2021 12:27:09 PM |
Good Time to buy? Looks to be recovering | JEvans1 | investorshub | 12/20/2020 10:47:05 PM |
maybe even the Grey Market ;-) | Disquisition | investorshub | 12/11/2020 7:12:10 PM |
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...